scholarly journals Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1630
Author(s):  
Mariana Rei ◽  
Sofia Raposo ◽  
Paulo Figueiredo ◽  
Rita Sousa ◽  
Luís Sá
Keyword(s):  
Tumor Biology ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
High Grade ◽  
Peritoneal Carcinoma ◽  
Non Invasive ◽  
Serous Borderline Tumor ◽  
And Behavior ◽  
Serous Tumors

Ovarian borderline serous tumors present with peritoneal involvement in 20% of cases, either as non-invasive or invasive implants, the latter also known as extraovarian low-grade serous carcinoma. The coexistence of high-grade serous carcinoma is rare, suggesting a synchronous neoplasia with a distinct and independent tumor biology and behavior. We aim to describe a case of a synchronous ovary-peritoneum neoplasia: serous borderline tumor and primary peritoneal high-grade serous carcinoma. A discussion and literature review concerning the optimal diagnostic and therapeutic approach is provided.

scholarly journals Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1630
Author(s):  
Mariana Rei ◽  
Sofia Raposo ◽  
Paulo Figueiredo ◽  
Rita Sousa ◽  
Luís Sá
Keyword(s):  
Tumor Biology ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
High Grade ◽  
Peritoneal Carcinoma ◽  
Non Invasive ◽  
Serous Borderline Tumor ◽  
And Behavior ◽  
Serous Tumors

Ovarian borderline serous tumors present with peritoneal involvement in 20% of cases, either as non-invasive or invasive implants, also known as extraovarian low-grade serous carcinoma. The coexistence of high-grade serous carcinoma is rare, suggesting a synchronous neoplasia with a distinct and independent tumor biology and behavior. We aim to describe a case of a synchronous ovary-peritoneum neoplasia: serous borderline tumor and primary peritoneal high-grade serous carcinoma. A discussion and literature review concerning the optimal diagnostic and therapeutic approach is provided.

Malignant Transformation of a Serous Borderline Tumor and Early Metastasis of Associated Low-Grade Serous Carcinoma Detected on Screening Mammography

2011 ◽  
Vol 29 (30) ◽  
pp. e763-e765 ◽  
Author(s):  
Donata Rohsbach ◽  
Fabian Trillsch ◽  
Marc Regier ◽  
Matthias Choschzick ◽  
Friedrich Kommoss ◽  
...  
Keyword(s):  
Malignant Transformation ◽  
Screening Mammography ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
Early Metastasis ◽  
Serous Borderline Tumor

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

2008 ◽  
Vol 18 (3) ◽  
pp. 487-491 ◽  
Author(s):  
R. SALANI ◽  
R. J. KURMAN ◽  
R. GIUNTOLI ◽  
G. GARDNER ◽  
R. BRISTOW ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Mutation Frequency ◽  
Clinical Stage ◽  
Serous Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Mutation Status ◽  
Tumor Dna ◽  
Serous Tumors

The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of TP53 using purified epithelial samples has not yet been performed to accurately assess the mutation frequency and to correlate it with the histologic grade. The purpose of this study was to assess the TP53 mutational profile in a relatively large series of high-grade (53 primary and 18 recurrent) and 13 low-grade ovarian serous tumors using DNA isolated from affinity-purified tumor cells and to correlate it with in vitro drug resistance. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4–9. In vitro drug resistance assays to carboplatin, cisplatin, paclitaxel, and taxotere were performed on the same tumor samples and correlated with the TP53 mutation status. TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13 low-grade serous tumors (an invasive low-grade serous carcinoma). The mutations were predominantly missense mutations (59.6%). TP53 mutations were associated with high-grade serous carcinomas and recurrent disease (P < 0.0001). There was no statistically significant correlation between TP53 mutation status and drug resistance assays or clinical stage (P > 0.25). The frequency of TP53 mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than previously reported. Furthermore, we found that TP53 is not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas.

Assessing the landscape of ovarian serous borderline tumors

2019 ◽  
Vol 29 (3) ◽  
pp. 572-578 ◽  
Author(s):  
Irini Messini ◽  
Triada Doulgeraki ◽  
Dimitris Chrysanthakis ◽  
Petros Yiannou ◽  
Theofani Gavresea ◽  
...  
Keyword(s):  
Univariate Analysis ◽  
Lymph Node Involvement ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumors ◽  
Non Invasive ◽  
Node Involvement ◽  
Serous Tumor ◽  
Serous Tumors ◽  
Micropapillary Pattern

AimTo compare distinct clinicopathological features between atypical proliferative serous tumors and non-invasive low-grade ovarian serous carcinomas.MethodsOur study group comprised 203 cases of serous borderline tumors sub-classified as atypical proliferative serous tumors or as non-invasive low-grade serous carcinomas. All pathological features related to borderline tumors were re-evaluated by two gynecological pathologists. Data concerning recurrences and survival were retrieved from the medical records of the patients.ResultsWhen comparing atypical proliferative serous tumors to non-invasive low-grade serous carcinomas, the latter were statistically related to advanced stage at diagnosis, bilateral disease, exophytic pattern of growth, microinvasive carcinoma, and the presence of invasive implants. In univariate analysis, recurrences were statistically related to the exophytic pattern of growth, to microinvasion, and to the presence of implants (both invasive and non-invasive). Nevertheless, in multivariate analysis, only microinvasion and the presence of invasive implants were related to recurrence. Women who eventually succumbed to the disease were only those with invasive implants. Their ovarian tumor was either a non-invasive low-grade serous carcinoma or an atypical proliferative serous tumor with ‘minimal’ micropapillary pattern. Neither lymph node involvement nor endosalpingiosis seemed to influence the course of the disease.ConclusionsThe results of our study underline the increased possibility of non-invasive low-grade serous carcinomas to be related with features indicative of aggressive behavior as opposed to atypical proliferative serous tumors. Nevertheless, irrespective of tumor histology, the presence of invasive implants and microinvasion were the only independent prognostications of recurrence.

Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases

2017 ◽  
Vol 27 (9) ◽  
pp. 2006-2013 ◽  
Author(s):  
Nataša Kenda Šuster ◽  
Snježana Frković Grazio ◽  
Irma Virant-Klun ◽  
Ivan Verdenik ◽  
Špela Smrkolj
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Signal Intensity ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Clinical Parameters ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Nanog Expression ◽  
Serous Tumors

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG–slightly positive, NANOG–moderately positive, and NANOG–strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.ResultsA specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.ConclusionsPositive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.

scholarly journals A mini-review regarding the carcinogenesis and morphology of serous tumors of the ovary, fallopian tube and peritoneum

2021 ◽  
Vol 8 (1) ◽  
pp. 44-52
Author(s):  
Tiberiu-Augustin Georgescu ◽  
Roxana Bohiltea ◽  
Octavian Munteanu ◽  
Corina Grigoriu ◽  
Ioana Paunica ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Female Genital Tract ◽  
Molecular Classification ◽  
Genetic Alterations ◽  
Serous Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Cancer Pathogenesis ◽  
Well Differentiated ◽  
Serous Tumors

Similar to the already well-recognized adenoma-carcinoma sequence in colorectal cancer pathogenesis, it has been believed for many decades that the progression of ovarian epithelial tumors occurs from benign serous cystadenomas to borderline tumors, to well-differentiated carcinomas, and ultimately, to poorly differentiated carcinomas. However, it is currently accepted that low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC) are fundamentally different tumor types and, consequently, different diseases. In fact, whereas the benign-borderline-malignant sequence seems to apply quite well to low-grade serous carcinoma, the sequence of genetic alterations in high-grade serous carcinoma is substantially different. In this mini-review, we included the current consensus regarding the morphological and etiopathogenic results regarding serous tumors of the ovary, fallopian tube and peritoneum. It also briefly describes the history of benign, borderline and malignant serous tumors, discussing multiple types of dichotomies in serous carcinomas of the female genital tract and summarizing the current molecular classification.

MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor

2020 ◽  
Vol 38 (8) ◽  
pp. 782-789
Author(s):  
Masaya Kawaguchi ◽  
Hiroki Kato ◽  
Yuichiro Hatano ◽  
Hiroyuki Tomita ◽  
Akira Hara ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
Imaging Findings ◽  
Serous Borderline Tumor ◽  
Carcinoma Of The Ovary
Sign in / Sign up

Export Citation Format

Share Document